4 results
The objective is to compare the efficacy and safety of masitinib 12 mg/kg/day to sinutinib 50 mg/day
Safety and efficacy objectives:The objective is to compare the safety and efficacy of masitinib at 6 of 7.5 mg/kg/day to imatinib at 400 or 600 mg, in patients with gastro-intestinal stromal tumour in first line medical treatment.
Primary:The primary objective of Study 218MS305 is to determine whether prolonged-release fampridine (10 mg BID) has a clinically meaningful effect on patient-reported walking ability over a 24-week study period.Secondary:The secondary objectives…
To examine whether compromised cochlear microphonic (CM) response during cochlear implant surgery results in poorer acoustic hearing preservation compared to preserved CM.